AR030882A1 - Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion - Google Patents

Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion

Info

Publication number
AR030882A1
AR030882A1 ARP010104792A ARP010104792A AR030882A1 AR 030882 A1 AR030882 A1 AR 030882A1 AR P010104792 A ARP010104792 A AR P010104792A AR P010104792 A ARP010104792 A AR P010104792A AR 030882 A1 AR030882 A1 AR 030882A1
Authority
AR
Argentina
Prior art keywords
transcription terminator
mutation
microbies
dangerous
compositions
Prior art date
Application number
ARP010104792A
Other languages
English (en)
Original Assignee
Megan Health Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megan Health Inc, Univ Washington filed Critical Megan Health Inc
Publication of AR030882A1 publication Critical patent/AR030882A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se revelan composiciones que comprenden un microbio que tiene una mutacion atenuante que comprende una insercion de un terminador de transcripcion recombinante en un gen cromosomico. Las composiciones pueden ser usadas como vacunas o vehículos portadores para suministrar una proteína deseada a un individuo. También se revelan métodos para inmunizar a un individuo y métodos para suministrar un producto de gen deseado a un individuo en base a la administracion de las composiciones.
ARP010104792A 2000-10-12 2001-10-12 Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion AR030882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68912300A 2000-10-12 2000-10-12

Publications (1)

Publication Number Publication Date
AR030882A1 true AR030882A1 (es) 2003-09-03

Family

ID=24767139

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104792A AR030882A1 (es) 2000-10-12 2001-10-12 Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion

Country Status (7)

Country Link
EP (1) EP1326960B1 (es)
AR (1) AR030882A1 (es)
AT (1) ATE284440T1 (es)
AU (1) AU2002211582A1 (es)
CA (1) CA2463482A1 (es)
DE (1) DE60107707T2 (es)
WO (1) WO2002030457A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134659A1 (en) * 2003-04-18 2007-06-14 Warnex Reasearch, Inc. Polynucleotides for the detection of salmonella species
EP2150616A4 (en) 2007-05-10 2011-07-27 Univ Arizona REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY
WO2009046449A1 (en) 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
EP2526185A4 (en) 2010-01-22 2013-07-24 Univ Arizona BACTERIUM WITH REGULATED RFAH NUCLEIC ACID
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2112220A3 (en) * 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
GB9804809D0 (en) * 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto

Also Published As

Publication number Publication date
AU2002211582A1 (en) 2002-04-22
EP1326960A2 (en) 2003-07-16
DE60107707D1 (de) 2005-01-13
WO2002030457A3 (en) 2003-01-23
EP1326960B1 (en) 2004-12-08
WO2002030457A2 (en) 2002-04-18
CA2463482A1 (en) 2003-04-18
DE60107707T2 (de) 2005-12-08
ATE284440T1 (de) 2004-12-15
WO2002030457A9 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
HK1082187A1 (en) Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
AR030882A1 (es) Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
IL145982A0 (en) Vaccines
DK1187613T3 (da) Amidsubstituerede imidazoquinoliner
ATE268353T1 (de) Verfahren zur herstellung von mit antioxidant gedoptem uhmwpe und daraus hergestelltes implantat
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
DE69929313D1 (de) Verfahren und zusammensetzungen zur verabreichung von taxanen
DE60142031D1 (de) Viskoelastische substanzen zur verwendung bei mittelohr operationen
WO2004053072A3 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
MX2023003762A (es) Vacunas de arn mensajero contra un amplio espectro de variantes de coronavirus.
MX2010001014A (es) Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos.
IL150190A0 (en) Method and formulation for treating resistance to antihypertensives and related conditions
HK1064108A1 (en) Agent for the prevention and treatment of sexually transmitted diseases-i
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
WO2001052855A3 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
NO996074L (no) Voksestere anriket i <omega>-3 umettede fettsyrer, deres fremstilling og deres anvendelse
WO2001068829A3 (en) Genetically stable cholera vaccines
WO2003099193A3 (en) Vaccines
WO2002100317A3 (en) Targeted particles and methods of using the same

Legal Events

Date Code Title Description
FB Suspension of granting procedure